tirzepatide for the treatment of obstructive sleep apnea FDA approves weight-loss drug Zepbound to treat Tirzepatide in Obesity-Related Obstructive Sleep

When people who are overweight and obese stopped taking their weight-loss medications they regained weight faster than those who stopped a diet or exercise program, a new review of studies finds.

What are your thoughts on integrating semaglutide into clinical practice for liver diseaseor broader metabolic care

Infantile neuroaxonal dystrophy (INAD) is a rare paediatric neurodegenerative condition caused by mutations in the PLA2G6 gene, which is also the causative gene for PARK14-linked young adult-onset dystonia parkinsonism

Payors gain a clearer pathway to lower dispensing costs and broader access

Dysbiosisan imbalance in the microbiomeleads to increased appetite and the rise of metabolic disorders, both fuel obesity and its issues

Key Features: Exosome-infused patches for enhanced efficacy